Loading
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Latest quote
$1.69
+$0.01 · +0.60%
After-hours
$1.67
−$0.02 · -1.18%
Oct 9, 5:25 PM ET
Regular session · ET · Market data may be delayed.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Day range
Current $1.69
52-week range
Current $1.69
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
42
Mixed
Risk
89
Extreme Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Day range
Current $1.69
52-week range
Current $1.69
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 723.35K USD | — | — | — | — |
| Gross profit | −723.35K USD | — | — | — | — |
| Research and development | 42.36M USD | 18.7M USD | 5.82M USD | 6.01M USD | 2.93M USD |
| Selling, general, and administrative | 15.8M USD | 17.73M USD | 7.85M USD | 6.09M USD | 4.92M USD |
| Operating expenses | 57.44M USD | 30.19M USD | 34.74M USD | 18.31M USD | 7.85M USD |
| Interest income | 1.88M USD | 3.26M USD | 99.97K USD | 19.01K USD | 3 USD |
| Interest expense | — | 967.6K USD | 906.27K USD | 663.77K USD | 767.51K USD |
| Depreciation and amortization | 723.35K USD | 298.64K USD | 124.25K USD | 115K USD | 34.13K USD |
| Operating income | −58.16M USD | −30.19M USD | −34.74M USD | −18.31M USD | −7.85M USD |
| Net income | −55.92M USD | −26.57M USD | −37.64M USD | −19.48M USD | −8.52M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
610.06% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
